Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer

Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer

BackgroundAromatase inhibitors (AI) reduce recurrence and death in patients with early-stage hormone receptor-positive (HR +) breast cancer. Treatment-related toxicities, including AI-induced musculoskeletal symptoms (AIMSS), are common and may lead to early AI discontinuation. The objective of this...

Full description

Bibliographic Details
Main Authors: Daniel L. Hertz, Karen Lisa Smith, Yuhua Zong, Christina L. Gersch, Andrea M. Pesch, Jennifer Lehman, Amanda L. Blackford, N. Lynn Henry, Kelley M. Kidwell, James M. Rae, Vered Stearns
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Genetics
Subjects:
Pharmacogenetics
aromatase inhibitor
Musculoskeletal adverse events
OPG
TCL1A
breast cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2021.662734/full

Internet

https://www.frontiersin.org/articles/10.3389/fgene.2021.662734/full

Similar Items